Literature DB >> 10471051

p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.

J Schneider1, P Presek, A Braun, P Bauer, N Konietzko, B Wiesner, H J Woitowitz.   

Abstract

The oncogene product epidermal growth factor receptor (EGF-R), the tumour suppressor gene product p53 and anti-p53 antibodies are detectable in the serum of certain cancer patients. Increased levels of some of these products were reported in lung cancer patients after occupational asbestos exposure and after exposure to polycyclic aromatic hydrocarbons or vinylchloride. In the first step, this study investigated the possible diagnostic value of serum EGF-R, p53-protein and anti-p53 antibodies, measured by an enzyme-linked immunosorbent assay, in lung tumour patients. In addition to being investigated on a molecular epidemiological basis, these parameters were examined as biomarkers of carcinogenesis, especially with regard to asbestos incorporation effects or of radon-induced lung cancers. Also, a possible effect of cigarette smoking and age dependence were studied. A total of 116 male patients with lung or pleural tumours were examined. The histological classification was four small-cell cancers, six large-cell cancers, 32 adenocarcinomas, 47 squamous carcinomas, 12 mixed lung carcinomas, five diffuse malignant mesotheliomas and ten lung metastasis of extrapulmonary tumours. Twenty-two lung cancers and all mesotheliomas were related to asbestos, 22 lung cancers were related to ionizing radiation and 61 patients had cigarette smoke-related lung cancer. Besides these patients 50 male patients with non-malignant lung or pleural diseases were included; of the latter eight subjects suffered from asbestosis. Controls were 129 male subjects without any lung disease. No significantly elevated or decreased serum values for p53 protein, EGF-R, or anti-p53 antibodies as a function of histological tumour type, age, or degree and type of exposure (asbestos, smoking, ionizing radiation) could be found. The utility of p53-protein, EGF-R and anti-p53 antibodies as routine biomarkers for screening occupationally derived lung cancers is limited.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471051      PMCID: PMC2363153          DOI: 10.1038/sj.bjc.6690632

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  40 in total

Review 1.  Epidermal growth factor in breast cancer.

Authors:  S Barker; G P Vinson
Journal:  Int J Biochem       Date:  1990

2.  Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure.

Authors:  K Husgafvel-Pursiainen; A Kannio; P Oksa; T Suitiala; H Koskinen; R Partanen; K Hemminki; S Smith; R Rosenstock-Leibu; P W Brandt-Rauf
Journal:  Environ Mol Mutagen       Date:  1997       Impact factor: 3.216

3.  Elevated serum levels of pantropic p53 proteins in chromium workers.

Authors:  T Hanaoka; Y Yamano; N Katsuno; J Kagawa; S Ishizu
Journal:  Scand J Work Environ Health       Date:  1997-02       Impact factor: 5.024

4.  Epidermal growth factor receptor in adenocarcinoma of the kidney.

Authors:  K E Ambs; A Takahashi; F Hering; S Costa; P R Huber
Journal:  Urol Res       Date:  1989

5.  Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients.

Authors:  G Sozzi; M Miozzo; E Tagliabue; C Calderone; L Lombardi; S Pilotti; U Pastorino; M A Pierotti; G Della Porta
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

6.  Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer.

Authors:  M R Rosenfeld; N Malats; L Schramm; F Graus; F Cardenal; N Viñolas; R Rosell; M Torà; F X Real; J B Posner; J Dalmau
Journal:  J Natl Cancer Inst       Date:  1997-03-05       Impact factor: 13.506

7.  Measurement of serum p53 protein in patients with small cell lung cancer and results of its clinicopathological evaluation.

Authors:  Y Segawa; N Takigawa; K Mandai; Y Maeda; I Takata; N Fujimoto; K Jinno
Journal:  Lung Cancer       Date:  1997-03       Impact factor: 5.705

8.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners.

Authors:  K H Vähäkangas; J M Samet; R A Metcalf; J A Welsh; W P Bennett; D P Lane; C C Harris
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

Review 9.  Biochemical and molecular epidemiology of cancer.

Authors:  H Sugimura; A Weston; N E Caporaso; P G Shields; E D Bowman; R A Metcalf; C C Harris
Journal:  Biomed Environ Sci       Date:  1991-06       Impact factor: 3.118

10.  Epidermal growth factor receptor expression in human lung cancer cell lines.

Authors:  M Haeder; M Rotsch; G Bepler; C Hennig; K Havemann; B Heimann; K Moelling
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

View more
  7 in total

1.  Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells.

Authors:  Bin-Wen Wu; Yuan Wu; Jia-Long Wang; Ju-Sheng Lin; Shu-Yu Yuan; Ai Li; Wu-Ren Cui
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

2.  Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls.

Authors:  Min Wu; Chen Mao; Qing Chen; Xin-Wei Cu; Wei-Seng Zhang
Journal:  Mol Biol Rep       Date:  2009-08-20       Impact factor: 2.316

3.  Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment.

Authors:  I Kappers; M A Vollebergh; H van Tinteren; C M Korse; L L Nieuwenhuis; J M G Bonfrer; H M Klomp; N van Zandwijk; M M van den Heuvel
Journal:  Ecancermedicalscience       Date:  2010-11-03

4.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

5.  Comparative proteomic analysis in serum of former uranium miners with and without radon induced squamous lung cancer.

Authors:  Simone Helmig; Günter Lochnit; Joachim Schneider
Journal:  J Occup Med Toxicol       Date:  2019-03-15       Impact factor: 2.646

Review 6.  Autoantibodies as diagnostic biomarkers for lung cancer: A systematic review.

Authors:  Bin Yang; Xiaoyan Li; Tianyi Ren; Yiyu Yin
Journal:  Cell Death Discov       Date:  2019-08-05

7.  Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma.

Authors:  Y Lemos-González; F J Rodríguez-Berrocal; O J Cordero; C Gómez; M Páez de la Cadena
Journal:  Br J Cancer       Date:  2007-04-24       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.